An overnight switch to ropinirole therapy in patients with Parkinson's disease
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
Patients with Parkinson's disease (n = 68) switched from per-golide or bromocriptine to ropinirole overnight (dose equivalence ratios – 1 : 6 and 10 : 6, respectively). The activities of daily living score for the Unified Parkinson's Disease Rating Scale (UPDRS) was significantly improved 4 weeks after the bromocriptine–ropinirole switch. All other UPDRS scores, including that for the side-effect component, were not significantly different after either switch. Overnight switching may be a safe therapeutic approach that may reduce hospitalisation and related socio-economic costs.
- An overnight switch to ropinirole therapy in patients with Parkinson's disease
Journal of Neural Transmission
Volume 106, Issue 9-10 , pp 925-929
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Keywords: Ropinirole
- Parkinson's disease.
- Industry Sectors